25 results about "Prostaglandin" patented technology

This invention provides a method for the simultaneous and rapid detection of four oxidative stress-related biomarkers and its application. The detection method includes: (S1) pretreatment of samples using a protein precipitation extract to simultaneously extract four target compounds: 8-hydroxydeoxyguanosine, 8-isoprostaglandin F2β, 8-isoprostaglandin F2α, and acetyllysine, and preparing a test solution; the protein precipitation extract is a methanol-acetonitrile-perchloric acid mixed solution containing formic acid, wherein the volume ratio of methanol, acetonitrile, and perchloric acid is (8-10):(8-10):(0.5-1), and the volume concentration of formic acid is 0.1-0.5%; (S2) detection of the test solution and standard solution using liquid chromatography-tandem mass spectrometry, and matrix calibration using an internal standard method; plotting a standard curve with the peak area ratio of the target compound to the internal standard as the ordinate and the concentration as the abscissa; and calculating the concentration of the target compound in the test solution based on the standard curve.

A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable bicyclic prostaglandin; L is a linker group; and at least one co-monomer of Formula III J-(Y1-A)n, J represents a linking functional group, n is 2 to 8 preferably 3 to 8; Y1 comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched C1 to C10 alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.

The application belongs to the technical field of microorganisms, and provides a Streptococcus salivarius subsp. thermophilus HX-ST36, which has a preservation number of CGMCC NO. 32955. The Streptococcus salivarius subsp. thermophilus provided by the application can ferment Astragalus membranaceus Bunge-Angelica sinensis. In a cold coagulation and blood stasis type primary dysmenorrhea model mouse, the fermentation product thereof can significantly inhibit the writhing response, and can realize the effects of relieving dysmenorrhea and tonifying blood by reducing the levels of prostaglandin PGF2 and vasopressin ADH in uterine tissue and increasing the hemoglobin (HGB) content. The effect of the fermentation product in removing dampness is verified by improving the dampness signs of a crowd. The application further provides a probiotic preparation and a preparation method of a probiotic fermentation product. The preparation method of the probiotic preparation and the probiotic fermentation product is simple and can be produced on a large scale.

This invention discloses a rifaximin nanoemulsion, its preparation method, and its application, belonging to the field of veterinary drug technology. The technical solution includes a rifaximin nanoemulsion comprising rifaximin, a compound essential oil, a surfactant, a co-surfactant, and water; the compound essential oil includes oregano oil, cinnamon oil, and tea tree oil. This invention prepares a rifaximin nanoemulsion using a compound of oregano, cinnamon, and tea tree oils as the oil phase, exhibiting both high antibacterial efficiency and high safety. The three essential oils have a synergistic antibacterial effect, complementing rifaximin through multi-target action, broadening the antibacterial spectrum, and showing significant inhibitory effects against various bacteria and fungi. It can enhance uterine smooth muscle contraction function by stimulating the synthesis and secretion of prostaglandins and oxytocin, providing potential support for uterine involution and endometrial repair. After administration, it can effectively reduce the number of inflammatory cells such as leukocytes and neutrophils in experimental dairy cows, significantly reduce purulent vaginal discharge, and restore the softness and elasticity of the uterus upon rectal examination.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

This utility model discloses a prostaglandin vaginal capsule forming machine, relating to the technical field of capsule forming machines. It includes a support plate, with a slurry forming machine for producing prostaglandin vaginal capsules mounted on the top rear end of the support plate. The slurry forming machine has external auxiliary components for cutting. These auxiliary components include a mounting bracket mounted on the support plate, located at the front of the slurry forming machine. This utility model uses a dual-axis motor to drive a movable bracket, which is limited by a positioning bracket. The movable bracket then drives a cutter to cut the capsule. Because the unloading plate and the cutter move in contact, the slurry adhering to the cutter is pushed off by the unloading plate. Furthermore, because the unloading plate is supported by a telescopic rod and a spring, it can slowly push the slurry, avoiding excessive pressure that could scatter the slurry or hinder subsequent capsule forming. This prevents the slurry from adhering to the outside of the cutter, thus avoiding affecting the feeding efficiency and cutting effect.

Provided herein are methods for reducing reactive microglia in a subject. Further provided herein are methods for treating a neurological disease, disorder, or condition in a subject. In some cases, the methods involve administering a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor to the subject. In some cases, the 15-PGDH inhibitor can penetrate the blood-brain barrier.

This invention discloses the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders and the related pharmaceutical formulation. It belongs to the field of biomedical technology, and specifically relates to the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders. Through chronic restraint stress (CRS) mouse models, corticosterone-induced (CORT)-damaged PC12 cell models, and multi-level molecular, circuit, and behavioral analyses, this invention demonstrates that prostaglandin A2 can exert multi-target anti-anxiety effects at the levels of overall behavior, cellular function, neural circuit structure, and molecularity. Prostaglandin A2 can treat anxiety disorders by improving anxiety-like behaviors and reversing behavioral phenotypic damage.

The invention relates to the field of cosmetology, dermatology and medicine, and is concerned with the development and production of a combination, and also of a composition based thereon, for hair growth enhancing in mammals and / or for preventing and / or treating alopecia, primarily in humans, and more particularly to combinations based on derivatives of F- and E-type prostaglandins, characterized by the absence of undesirable side-effects, and also to a stable composition comprising said combination. The use of a combination of prostaglandins in a single composition makes it possible to simultaneously activate a plurality of physiological processes, including stimulating a hair follicle to produce a new hair, increasing the local microcirculation in the area adjacent to the hair follicle, and reducing the aggregation of thrombocytes, thereby preventing thrombogenesis in the capillary network. Furthermore, the presence in the combination or in the composition based thereon of modified prostaglandins carrying a group of nitrogen oxide donors enables better penetration of other ingredients of the combination or composition into the skin.

The present disclosure relates to pharmaceutical formulations comprising uterotonic prostaglandins for use in treatment of postpartum hemorrhage. In particular, the disclosure relates to one or more topically administered formulations in solid, liquid, or semi-solid dosage forms comprising nano-structured carriers and uterotonic prostaglandins and / or acceptable salts thereof, providing alternative routes of administration.

The present invention relates to compounds of formula (I)to salts, solvates and solvates of salts thereof, and to pharmaceutical compositions comprising these compounds as active ingredients. The invention further relates to their use as aldo-keto reductase family 1 C3 (AKR1C3), also known as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5, HSD17B5) and prostaglandin (PG) F2α synthase, inhibitors. The invention further relates to methods for their preparation, and to uses of said compounds.

This invention relates to the field of chemical intermediates technology, specifically disclosing a chiral prostaglandin intermediate and its synthesis process. This invention provides a novel synthesis method for chiral prostaglandin intermediates, for example (…). R , E )-3-((tert-butyldiphenylsilyl)oxy)- N -Methoxy- N 4-Methylhexyl-enamide: This process is simple to operate, uses inexpensive raw materials, and has mild reaction conditions, making it suitable for industrial production. The addition of an ethylthio group side arm as a chiral auxiliary improves the chiral control and selectivity of the aldol condensation reaction. It also utilizes inexpensive and readily available ( ) R The formation of chirality is induced by the Evans chiral cofactor of 4-benzyl-2-oxazolidinone. In the Zhang enyne ring isomerization reaction, the catalyst prepared by (Sc,Rp)-Duanphos has high activity and reduces the amount of Rh metal, making the process cost-effective.

This invention proposes a method for isocarbonyl hyperventilation to protect alveolar epithelial cells from oxidative damage. It belongs to the field of medical respiratory therapy technology. The method includes: providing patients requiring respiratory support with a minute ventilation volume higher than physiologically required, while simultaneously supplementing the inhaled air with exogenous carbon dioxide using a gas mixing device; continuously monitoring the patient's end-tidal carbon dioxide partial pressure, the concentration of 8-isoprostaglandin in exhaled condensate, and pH value, among other oxidative stress biomarkers, using monitoring equipment; and precisely regulating gas composition and ventilation parameters through isocarbonyl hyperventilation to create a suitable microenvironment for alveolar epithelial cells, effectively neutralizing excessive intracellular oxidative substances, reducing direct damage to cells from oxidative stress, and decreasing adverse effects such as cell membrane lipid peroxidation and protein denaturation, thereby significantly improving the survival rate and normal function maintenance capacity of alveolar epithelial cells.

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for treating ocular diseases or conditions, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods comprise steroids and prostaglandins that exhibit anti-inflammatory activity, reduce intraocular pressure (IOP), and / or other desirable activities. Injection of the compositions in the eye provides therapeutic benefits to patients suffering from ocular conditions.

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

This invention belongs to the field of biomedicine, specifically relating to the use of gemmaconazole in the preparation of drugs for treating primary dysmenorrhea. Gemarazole of this invention can significantly reduce the release of prostaglandins in uterine tissue, thereby relieving uterine smooth muscle spasms, reducing endometrial congestion and inflammatory responses, and thus alleviating pain, thus playing a role in treating primary dysmenorrhea. This provides a new option for clinical treatment of primary dysmenorrhea and has good application prospects.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

The application discloses a polyketone compound, a preparation method thereof and application of the polyketone compound in Cox2 enzyme inhibition and anti-inflammatory drugs, and has the characteristics that the structural formula of the compound is shown as I, the preparation method steps include obtaining a fermentation product containing the polyketone compound through fermentation culture of a strain, then soaking the fermentation product with ethyl acetate to obtain a crude extract, and on the basis, obtaining the crude extract through normal-phase silica gel column chromatography, reverse-phase medium-pressure column chromatography and semi-preparative high performance liquid chromatography separation and purification, and the polyketone compound has obvious anti-inflammatory activity; and the polyketone compound can significantly inhibit the generation of nitric oxide, active oxygen and prostaglandin E2 and inhibit COX-2 enzyme activity, and is expected to become an active drug molecule for inflammation treatment.

This invention provides the application of swertisin in the preparation of drugs for treating insomnia. Through Western blotting experiments, this invention found that ERK phosphorylation can be dose-dependently activated by Swertisin, demonstrating that Swertisin has an agonistic effect on EP4 and can bind to the EP4 protein, thereby protecting EP4 from denaturation and precipitation under organic reagent treatment. By constructing a zebrafish insomnia model, the therapeutic effect of Swertisin on insomnia was studied. The results showed that Swertisin exhibited a concentration-dependent inhibitory effect on PTZ-induced insomnia-like activity; as the concentration increased, the zebrafish's movement trajectory gradually became sparser, showing a sedative-hypnotic potential similar to melatonin. Therefore, swertisin can be used to prepare an agonist of the prostaglandin receptor EP4, thereby effectively treating insomnia.

The application discloses a wheat Tilletia indica-specific biomarker combination, a screening method and application thereof, and the biomarker combination comprises 20-hydroxyarachidonic acid, 1-octadecyl lysophosphatidic acid, linolenic acid, 13-hydroxydocosahexaenoic acid, 4-methoxy estrone, hypoxanthine, 3-hydroxymyristic acid, beta-ecdysterone, 17-phenyltrinorprostaglandin F2 alpha cyclopropylmethylamide, 11,12-dihydroxyeicosatrienoic acid and oxidized octadecadienoic acid. When the biomarker combination is used for identifying Tilletia indica, the time-consuming long and the accuracy easily interfered by the spore development stage limitations of traditional morphological identification are overcome; in view of the molecular level identification difficulty caused by the high genome homology of Tilletia indica and Tilletia controversa, the application digs the feature difference at the level of metabolomics, and constructs a specific chemical fingerprint, so that the technical bottleneck that the close relatives are difficult to accurately distinguish is effectively solved.

The application relates to the technical field of chemical intermediates, and particularly discloses a prostaglandin chiral intermediate and a synthesis process thereof. The application provides a new synthesis process of a prostaglandin chiral intermediate, such as (R, E)-3-((tert-butyldiphenylsilyl)oxy)-N-methoxy-N-methylhex-4-enamide. The process is simple in operation, low in raw material cost and mild in reaction condition, is suitable for industrial production, and has the advantages of better chiral control selectivity of the aldol condensation reaction due to the increase of the ethyl sulfide side arm, the use of cheap and easily available (R)-4-benzyl-2-oxazolidinone Evans chiral auxiliary to induce the formation of chirality, high activity of a catalyst prepared from (Sc, Rp)-Duanphos in the Zhang enyne ring isomerization reaction, and reduction of the Rh metal dosage, so that the process cost has a cost advantage.